Results 111 to 120 of about 58,504 (176)

Inhibiting Fatty Acid Oxidation Reverses Autophagy-Mediated Acquired Chemotherapy Resistance in Pancreatic Ductal Adenocarcinoma. [PDF]

Cancer Res
Woo SM, Kang JH, Choi W, Lee H, Jang H, Sim SH, Chun JW, Koh EB, Kim C, Ham W, Hong W, Kang M, Park J, Han S, Kim JW, Lee EW, Lee WJ, Kim SY.   +17 more
europepmc   +1 more source

NALIRIFOX in Japanese treatment-naïve patients with metastatic pancreatic adenocarcinoma: results from an open-label, phase II study. [PDF]

ESMO Gastrointest Oncol
Ueno M, Ikezawa K, Komatsu Y, Nagano H, Hisano T, Terashima T, Nio K, Morizane C, Shimizu S, Ozaka M, Ohyama H, Otsuru T, Sudo K, Mizuno N, Daniel C, Martín-Fernández L, Amellal N, Bernard K, Sasaki M.   +18 more
europepmc   +1 more source

Safety and efficacy of sotorasib plus panitumumab and FOLFIRI for previously treated KRAS G12C-mutated metastatic colorectal cancer in the CodeBreaK 101 phase Ib study. [PDF]

ESMO Open
Masuishi T, Strickler JH, Kuboki Y, Fakih M, Greil R, Galot R, Price TJ, Élez E, Siena S, Nolte-Hippenmeyer J, Nduka C, Strydom N, Xia C, Hong DS.   +13 more
europepmc   +1 more source

Irinotecan Modulates Immune Checkpoints in Neuroblastoma. [PDF]

Immunotargets Ther
Lapidus T, Zorde-Khvalevsky E, Jolani A, Goldstein G, Peled A.   +4 more
europepmc   +1 more source

Second-line raltitrexed plus irinotecan (SALIRI) with bevacizumab, cetuximab, or alone for metastatic colorectal cancer: a prospective multicenter cohort-based secondary analysis of the SALLY trial. [PDF]

J Gastrointest Oncol
Kou F, Wang X, Li J, Wang Z, Xu T.
europepmc   +1 more source

Irinotecan [PDF]

, 2020
openaire   +1 more source

Basal Marker ΔNp63α Is Enriched in Pancreatic Cancer Metastases but Not in Primary Tumors Post-Chemotherapy. [PDF]

Cancer Med
Ryan DH, Ohara Y, Kruhlak MJ, Zhang X, Lin M, Tai CH, Alewine C.   +6 more
europepmc   +1 more source